NCT00506142View on ClinicalTrials.gov

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Metastatic Malignant Uveal Melanoma
Interventions
DRUG

Marqibo® (vincristine sulfate liposomes injection)

"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."

Trial Locations (4)

19107

Thomas Jefferson University, Philadelphia

77030

University of Texas M.D. Anderson Cancer Center, Houston

80045

University of Colorado, Denver, Denver

90024

University of California, Los Angeles, Los Angeles

All Listed Sponsors
lead

Spectrum Pharmaceuticals, Inc

INDUSTRY

NCT00506142 - Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma | Biotech Hunter | Biotech Hunter